Which class is considered first-line pharmacologic therapy for osteoporosis?

• A. Bisphosphonates
• B. Denosumab
• C. Teriparatide
• D. Raloxifene

Answer: (A)

Bisphosphonates are used as the first-line pharmacologic therapy for osteoporosis because they are potent antiresorptives that reliably reduce bone resorption and fracture risk across multiple sites, with a long track record and broad use that makes them cost-effective and accessible. They work by binding to bone mineral and being ingested by osteoclasts during bone remodeling; inside osteoclasts, they disrupt the mevalonate pathway and promote osteoclast apoptosis, effectively slowing bone turnover. This decrease in bone resorption leads to stabilization and gradual increases in bone density, translating into lower rates of vertebral, nonvertebral, and hip fractures in many patients.

There are practical reasons these agents are favored as initial therapy. They come in convenient oral forms (like weekly or monthly dosing) and IV forms (such as yearly infusions) to support adherence. They have a well-established safety and efficacy profile, supported by decades of clinical data and guidelines. Of course, there are important safety considerations to manage, including potential gastrointestinal side effects with oral forms, and instructions to take the medication with a full glass of water and to remain upright for about 30 minutes to minimize esophageal irritation; renal function and calcium/vitamin D status should be monitored as needed.

Other options exist for specific circumstances but are not typically considered first-line. Denosumab is highly effective but is often reserved for those who cannot tolerate bisphosphonates or who have specific clinical needs; stopping it can lead to rebound bone loss, so it requires careful management. Teriparatide stimulates bone formation and is usually used in more severe cases or after antiresorptives have failed, and it is more costly with a finite treatment duration. Raloxifene can reduce vertebral fracture risk but has a less favorable impact on hip fractures and carries hormonal side effects, making it less universally appropriate as initial therapy.